Opinions expressed by Digital Journal contributors are their own.
DUSQ arrives in the United States with a simple, confrontational question: why did a decade of better sleep data still leave people exhausted at breakfast? The India-born sleeptech consumer company opens its US chapter on June 9 with a Kickstarter launch and a very public wager, positioning itself not as another wearable, but as what it calls the world’s only closed-loop sleep regulation system.
Behind the campaign sits a 12‑gram device that perches behind the ear and listens to the body while its owner sleeps. According to the company, it detects autonomic disruptions in real time and answers them with targeted stimulation of the vagus and vestibular nerves to pull sleepers back into deep rest before they fully wake. If the bet pays off, DUSQ will drag sleep technology from scorekeeping into what it frames as active intervention at the biological level.
From sleep scores to sleep regulation
Over the last ten years, mainstream sleep technology has trained consumers to obsess over scores, rings, charts, and marginal gains. DUSQ wants to close that chapter. The team argues that measuring sleep has reached diminishing returns, while the deeper nervous‑system problem has gone largely untouched. Their thesis is blunt: the next category is regulation, not tracking.
The co-founders describe today’s status quo as an industry that got very good at telling people how badly they slept while leaving the underlying biology almost unchanged. In their framing, high‑functioning professionals can follow every sleep hygiene rule, pop magnesium, optimize bedroom environments, and still wake up foggy, because their autonomic nervous system never fully downshifts at night. Micro‑arousals splinter deep sleep into fragments that no tracker prevents, and no supplement stops.
DUSQ’s device aims to live inside that hidden gap. Instead of stopping at pre‑bed routines, it starts working at dusk, then stays engaged through the full night. The company says its system reads nervous‑system activity through electrodermal signals and reacts in real time with adaptive stimulation, creating a closed loop between sensing and response. According to DUSQ, one completed clinical trial, with a second currently underway, showed improvements in deep sleep time, heart‑rate variability, and night awakenings, backed by more than 50 million physiological datapoints from its in‑house sleep laboratory.
The numbers matter because DUSQ insists it is a MedTech story, not a wellness story. Internal materials stress CDSCO certification in India and an FDA‑cleared stimulation modality for insomnia as core credibility pillars, even while the company remains careful to attribute all performance and regulatory claims to its own trials and documentation. The message: this is clinical proof first, marketing second.
The Indian lab that wants to redefine recovery in America
DUSQ’s origin sits far from the US crowdfunding crowd. The company grew out of an Indian sleep‑science lab built to study micro‑arousals and autonomic behavior at scale, collecting those tens of millions of datapoints before most American consumers had even heard its name. That scientific base helped secure around $3 million in seed funding, led by prominent Indian consumer venture firms and joined by angels from established healthcare and retail brands.
The founding team blends medical, commercial, and product firepower. Co‑founder Dr. Siddhant Bhargava, a physician and Forbes 30 Under 30 Asia honoree who has spent a decade building at the intersection of clinical medicine and consumer health, brings a personal history shaped by surviving Lupus as a teenager and cancer in his twenties. Those episodes drove his conviction that poor sleep plays a far bigger role in chronic illness than the industry admits, and that the autonomic nervous system should sit at the center of recovery, not the periphery.
The founding team includes Shalmali Kadu heading product, Mitansh Khurana leading tech, Animesh Kumar heading biotech, and Hrithik Jaiswal leading algorithms. Alongside them, Chief Taste Officer Gursakhi Lugani arrives as a second‑time founder who previously built a consumer brand from zero to 11 countries and into a landmark acquisition, and Growth Advisor Ronak Shah, co‑founder of Obvi, brings a track record of more than $100 million in sales.
Their first act played out at home. According to the company, DUSQ’s Gen 1 version reached more than 2,000 commercial users in India, boosted by a three‑Shark deal on Shark Tank India that turned the lab story into a national talking point. That early traction gave the team enough confidence to chase a harder stage: the mature US health‑tech market, where heavyweight names like Oura and Whoop dominate attention and pre‑sleep neurostimulation devices such as Somnee and Pulsetto pitch relaxation before bed.
DUSQ refuses to stand in that queue. Dr. Siddhant argues that those brands live in a different category entirely, locked into tracking and pre‑sleep priming while leaving the night itself largely untouched. Their counter‑move is sleep regulation as a stand‑alone class, with DUSQ claiming the right to define its rules. To drive that distinction home, the company has introduced SQ — Sleep Quotient. The entire sleep tech industry runs on lagging indicators: you wake up, your Oura gives you a 72, and there is nothing you can do about last night now. SQ is a leading indicator. It measures the body’s capacity to fall asleep before the night begins. In DUSQ’s language, the sleep score era is over.
“DUSQ exists to move sleep technology from observation to intervention, and in doing so, create an entirely new category.” Another sharpens the bet even further: “We don’t just track sleep. We regulate it. We’ve declared the death of the sleep score, a metric that has made the industry rich and left the user exactly where they started,” the company states.
Kickstarter as a category test
June 9, 2026, marked more than a crowdfunding date for DUSQ. The US Kickstarter launch functioned as a public stress test for the entire category thesis — and early numbers suggest a $1 million-plus opening, according to the company. The campaign offers founding tiers in roughly the mid-$200 range, with a planned retail price of $499 and shipping slated for August 2026.
The early response strengthens the claim that consumers are ready to move beyond dashboards and nightly grades. The sleep score habit, it turns out, may have shallower roots than the industry believed. The launch has dragged a behind-the-scenes category argument into the open — and the market appears to be listening.
From DUSQ’s perspective, the stakes stretch far beyond one campaign. Dr. Siddhant talks about defining and owning sleep regulation as a global category over the next decade, anchored in the autonomic nervous system as the true root of recovery. Their internal voice is unapologetically bold, leaning on lines such as “The next frontier of human performance isn’t another score. It’s restored biological function.” That rhetoric has now met its first real audience: exhausted professionals who care less about category theory and more about how they feel at 7 a.m.
The company argues that those people will not have to manage dashboards or tweak settings to benefit. DUSQ’s own language puts it bluntly: “You don’t manage it. You just wake up differently.” If that promise survives contact with reality in American bedrooms, the Indian lab that once watched micro-arousals on monitors could become the nucleus of a new corner of consumer medtech.
What is certain is that on June 9, a 12-gram device from India stepped onto a US stage crowded with wearables and wellness gadgets — and declared that the real competition was never on the wrist, but deep inside the nervous system, all along. The opening numbers suggest at least some of America agrees.